UBS Group AG Has $50.78 Million Holdings in argenex SE $ARGX

UBS Group AG increased its position in shares of argenex SE (NASDAQ:ARGX) by 12.3% during the fourth quarter, Holdings Channel reports. The fund owned 60,384 shares of the company’s stock after acquiring an additional 6,591 shares during the quarter. UBS Group AG’s holdings in argenex were worth $50,780,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Abound Wealth Management boosted its position in argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after acquiring an additional 32 shares during the period. Sound Income Strategies LLC acquired a new stake in shares of argenex during the fourth quarter worth approximately $28,000. Ameriflex Group Inc. acquired a new stake in shares of argenex during the third quarter worth approximately $32,000. Aventura Private Wealth LLC acquired a new stake in shares of argenex during the fourth quarter worth approximately $38,000. Finally, Sunbelt Securities Inc. acquired a new stake in argenex during the third quarter valued at $36,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Down 2.0%

NASDAQ:ARGX opened at $794.70 on Wednesday. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The firm has a market cap of $49.42 billion, a price-to-earnings ratio of 40.71, a P/E/G ratio of 1.33 and a beta of 0.46. The company’s 50 day moving average is $757.32 and its 200-day moving average is $818.15.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Saturday, February 14th. The company reported $8.02 EPS for the quarter. argenex had a net margin of 30.42% and a return on equity of 38.51%. Research analysts predict that argenex SE will post 24.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ARGX. Guggenheim cut their price target on argenex from $1,160.00 to $1,120.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Citizens Jmp raised their price objective on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research report on Friday, February 27th. Wedbush reaffirmed an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a research report on Monday, March 9th. Finally, HC Wainwright raised their price objective on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, argenex currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,016.22.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.